Tyra Biosciences, Inc. Common Stock
TYRA US90240B1061
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
Annual Performance 1
2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
-46% | -46% | 96% | -1% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Kaplan Gilla |
9.78 USD |
9,568 Sold |
93,596 USD |
17/06/2025 | 18/06/2025 |
Kaplan Gilla |
9.78 USD |
9,568 Sold |
93,596 USD |
17/06/2025 | 18/06/2025 |
Kaplan Gilla |
10.35 USD |
10 Sold |
104 USD |
17/06/2025 | 17/06/2025 |
Kaplan Gilla |
10.35 USD |
10 Sold |
104 USD |
17/06/2025 | 17/06/2025 |
Kaplan Gilla |
10.38 USD |
6,814 Sold |
70,726 USD |
12/06/2025 | 16/06/2025 |
Kaplan Gilla |
10.38 USD |
6,814 Sold |
70,726 USD |
12/06/2025 | 16/06/2025 |
Kaplan Gilla |
10.31 USD |
15,000 Sold |
154,583 USD |
12/06/2025 | 13/06/2025 |
Kaplan Gilla |
10.31 USD |
15,000 Sold |
154,583 USD |
12/06/2025 | 13/06/2025 |
Kaplan Gilla |
10.31 USD |
30,000 Sold |
309,255 USD |
12/06/2025 | 12/06/2025 |
Kaplan Gilla |
10.31 USD |
30,000 Sold |
309,255 USD |
12/06/2025 | 12/06/2025 |